Exhibit I

Query: SEQ ID NO: 47

<!--StartFragment-->RESULT 1
ADG89281
ID   ADG89281 standard; DNA; 23 BP.
XX
AC   ADG89281;
XX
DT   11-MAR-2004 (first entry)
XX
DE   Cancer detection method related oligonucleotide #229.
XX
KW   ss; cancer; gene expression;
KW   estrogen receptor-positive invasive breast cancer.
XX
OS   Homo sapiens.
XX
PN   WO2003078662-A1.
XX
PD   25-SEP-2003.
XX
PF   12-MAR-2003; 2003WO-US007713.
XX
PR   13-MAR-2002; 2002US-0364890P.
PR   18-SEP-2002; 2002US-0412049P.
XX
PA   (GENO-) GENOMIC HEALTH INC.
XX
PI   Baker JB, Cronin MT, Kiefer MC, Shak S, Walker MG;
XX
DR   WPI; 2003-767536/72.
XX
PT   Predicting clinical outcome for a patient diagnosed with cancer comprises
PT   determining the expression level of one or more genes, and compared to
PT   the amount found in a reference cancer tissue set.
XX
PS   Disclosure; SEQ ID NO 229; 198pp; English.
XX
CC   The invention relates to a method of predicting clinical outcome for a
CC   patient diagnosed with cancer by determining the expression level of one
CC   or more genes, or their expression products, selected from p53BP2,
CC   cathepsin B, cathepsin L, Ki67/MiB1, and thymidine kinase in a cancer
CC   tissue obtained from the patient, normalized against control gene(s), and
CC   compared to the amount found in a reference cancer tissue set. The
CC   specification also discloses an array comprising polynucleotides
CC   hybridizing to the following genes: FOXMI, PRAME, Bcl2, STKI5, CEGP1, Ki-
CC   67, GSTM1, CA9, PR, BBC3, NME1, SURV, GATA3, TFRC, YB-1, DPYD, GSTM3,
CC   RPS6KB1, Sro, Chk1, ID1, EstR1, p27, CCNBI, XIAP, Chk2, CDC25B, IGFIR,
CC   AK055699, PI3KC2A, TGFB3, BAGI1, CYP3A4, EpCAM, VEGFC, pS2, hENT1, WISP1,
CC   HNF3A, NFKBp65, BRCA2, EGFR, TK1, VDR, Contig51037, pENTI, EPHXI, IFIA,
CC   CDHI, HIF1t, IGFBP3, CTSB, Her2 and DIABLO, immobilized on a solid
CC   surface. The methods are useful for predicting clinical outcome for a
CC   patient diagnosed with cancer, classifying cancer, and predicting the
CC   likelihood of long-term survival of a breast cancer patient, or a patient
CC   diagnosed with invasive breast cancer or with estrogen receptor (ER)-
CC   positive invasive breast cancer. This sequence corresponds to an
CC   oligonucleotide used in the method of the invention.
XX
SQ   Sequence 23 BP; 6 A; 5 C; 6 G; 6 T; 0 U; 0 Other;

  Query Match   100.0%; Score 23; DB 10; Length 23;
  Best Local Similarity   100.0%; Pred. No. 0.0037;
  Matches   23; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

```
Qy          1 TCTGCAGAGTTGGAAGCACTCTA 23
              |||||||||||||||||||||||
Db          1 TCTGCAGAGTTGGAAGCACTCTA 23
<!--EndFragment-->
```